Some Alzheimer’s Blood Tests Are Racing Toward IVD Certification
Vendors of plasma p-tau217-based tests are filing with U.S. and European regulators for approval of fully automated, in vitro diagnostics.
ALL NEWS
6512 RESULTS
Sort By:
- Most Recent
- Most Commented
Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
To some, the findings suggest that non-AD pathologies, driven by other comorbidities, might contribute to cognitive decline in these populations.
AI to Spot ARIA? FDA Says Yes
The commercial software icobrain aria sharpened radiologists’ ability to accurately detect ARIA-E and ARIA-H. The FDA approved the technology for clinical use November 7.
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
In Madrid, researchers touted the benefits of plasma prescreening and showed baseline data on these early AD populations. Meanwhile, remternetug has begun Phase 3.
Tau Modification Drugs Take a Hit with Negative Trial
Lilly’s Phase 2 trial of its O-GlcNAcase inhibitor ceperognastat failed to meet clinical endpoints. The drug’s adverse events suggest potential off-target effects.
Finally, Therapeutic Antibodies Start to Reduce Tangles
Bepranemab results bolster hopes for antibodies targeting tau’s middle section. Whether tangle clearance will improve clinical outcomes remains unclear.
Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial
ARIA rates have been the same or lower than in the Phase 3 trial. About 9,000 people are being treated in the U.S., half as many in Japan. EMA reverses course, recommending approval.
Clinical Trials on Alzheimer's Disease (CTAD) 2024- 17th
Trontinemab Data Strengthen Hope for Brain Shuttles Donanemab: Small Tweak in Titration, Big Gain in Safety? Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial Finally, Therapeutic Antibodies Start to Reduce Tangles Tau Modification Dr
Donanemab: Small Tweak in Titration, Big Gain in Safety?
By starting at a low dose and upping it stepwise for four months, scientists nearly halved the risk of ARIA while preserving plaque clearance.
Trontinemab Data Strengthen Hope for Brain Shuttles
Trontinemab swooped into the brain and removed amyloid efficiently, while causing few cases of ARIA. One person with cerebrovascular pathology died.
That Mystery “Density” in α-Syn Fibrils: Polyphosphate, Anyone?
Modeling and recombinant protein chemistry suggest that strings of phosphate worm their way through the fibrils. Proof is still needed.
Remembering Bruce Albala, 70, Leader in BACE Inhibitor Development
Albala died suddenly while celebrating his 40th wedding anniversary.
Lysosomal Protein TMEM106b Is Tightly Linked to TDP-43, Tau Pathology
Neurons with TMEM106B aggregates lose nuclear TDP-43 in ALS models. In tauopathy models, they accumulate no p-tau.
A Match Made in Microglia? ApoE and Aβ Click in Lysosomes, Seeding Plaque
The fateful pairing may happen in microglial lysosomes, where ApoE forms fibrillar aggregates.
Some Plasma Proteins Bolster Phagocytosis and Metabolism in Microglia
In certain regions of the brain, microglia internalize proteins from the plasma. At least one of them—ApoA-I—supports microglial phagocytosis.
Current Filters
No filters selected